CompletedNot Applicable

Registry of Patients With Von WilLEbrand Disease Treated With Voncento®

France135 participantsStarted 2015-11-23

Plain-language summary

Description of the long-term evolution of patients with von Willebrand disease and treated with Voncento® and of the hemostatic efficacy in the prevention and the treatment of non-surgical bleeding episodes and prevention of surgical bleeding during 2 years after patient inclusion.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients suffering from constitutional von Willebrand disease for whom Desmopressin treatment is deemed ineffective or contraindicated * Patients suffering from von Willebrand disease and being treated or having been treated with Voncento® for the treatment of surgical and non-surgical bleeding episodes, the prophylaxis of surgical and non-surgical bleedings * Patients with no history or suspicion of inhibitors (judged on previous efficacy) Exclusion Criteria: * Refusal of the patient or the patient's legal representative to take part in the study; * Existence of a contraindication to the use of Voncento® treatment

What they're measuring

Global assessment by the patient and the investigator of the hemostatic efficacy of Voncento® in the management of non-surgical bleeding episodes

Timeframe: Up to 24 months

Number of non-surgical bleeding episodes per year

Timeframe: Up to 24 months

Number of administrations of Voncento® needed to treat a non-surgical bleeding episode and for the long term prophylaxis

Timeframe: Up to 24 months

Total dose of Voncento® (in IU/kg of VWF) needed to treat a non-surgical bleeding episode and for the long term prophylaxis

Timeframe: Up to 24 months

Trial details

NCT IDNCT04657887

SponsorCSL Behring

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-12-31

View on ClinicalTrials.gov More Von Willebrand Disease trials

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Global assessment by the patient and the investigator of the hemostatic efficacy of Voncento® in the management of non-surgical bleeding episodes

Timeframe: Up to 24 months

Number of non-surgical bleeding episodes per year

Timeframe: Up to 24 months

Number of administrations of Voncento® needed to treat a non-surgical bleeding episode and for the long term prophylaxis

Timeframe: Up to 24 months

Total dose of Voncento® (in IU/kg of VWF) needed to treat a non-surgical bleeding episode and for the long term prophylaxis

Timeframe: Up to 24 months